CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.
Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞治疗前进行恰当的衰弱评估有助于资源的有效利用和合适的患者选择。
衰弱是判断患者身体状况是否足以接受CAR-T 细胞治疗的重要考量,但不应成为阻止治疗的障碍。本研究旨在描述目前关于拟接受CAR-T 治疗的成人和儿童血液病患者衰弱问题的研究范围,以及衰弱对其治疗资格可能造成的影响。
依据乔安娜·布里格斯研究所指南,采用范围综述方法。检索CINAHL、Cochrane、Embase、Medline、PubMed、Google Scholar、ClinicalTrials.gov、clinicaltrialsregister.eu和euclinicaltrials.eu数据库,纳入2017年至2024年3月2日发表的研究。由独立评审团队使用Rayyan网络应用进行筛选。
综述纳入12项研究,研究设计各不相同;未发现CAR-T 治疗儿童的相关研究。CAR-T 治疗前的衰弱评估方式差异很大,其中ECOG评分是最常用工具。
在CAR-T 治疗前适当评估衰弱,有助于有效利用资源并合理筛选患者。老年综合评估以及纳入CAR HEMATOTOX等评估工具,可能有助于评估衰弱的CAR-T 患者。
Following the Joanna Briggs Institute guidelines, we adopted a scoping review methodology. Our search was conducted across the databases CINAHL, Cochrane, Embase, Medline, PubMed, Google Scholar, clinicaltrials.gov, clinical trials register.eu, and euclinicaltrials.eu for studies published from 2017 to March 2nd 2024. Studies were screened by independent teams of reviewers using the web application Rayyan.
Our review included 12 studies, with varied study designs. No study in a pediatric CAR T-cell setting was found. A wide variation in assessing frailty before CAR T-cell therapy was evident, with ECOG being the most frequently used assessment tool.
An appropriate frailty assessment before CAR T-cell therapy promotes the productive use of resources and proper patient selection. Using a geriatric assessment and incorporating an assessment tool such as the CAR HEMATOTOX has the potential for assessing frail CAR T-cell therapy patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。